Recro Pharma, Inc. (REPH) News

Recro Pharma, Inc. (REPH): $2.09

-0.01 (-0.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add REPH to Watchlist
Sign Up

Industry: Biotech


Ranked

of 461

in industry

Filter REPH News Items

REPH News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

REPH News Highlights

  • REPH's 30 day story count now stands at 4.
  • Over the past 19 days, the trend for REPH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about REPH are CDMO, MGP and MO.

Latest REPH News From Around the Web

Below are the latest news stories about Recro Pharma Inc that investors may wish to consider to help them evaluate REPH as an investment opportunity.

Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego Facility

Full Scope of New Service Capabilities to be Operational in Q2; Company Has Already Secured Project Commitments from Multiple New ClientsSAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophil

Yahoo | February 23, 2022

Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022

Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. EasternSAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market

Yahoo | February 22, 2022

Recro Pharma (NASDAQ:REPH) investors are sitting on a loss of 80% if they invested three years ago

As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an...

Yahoo | February 8, 2022

Frontier Wealth Management LLC Buys Rio Tinto PLC, T-Mobile US Inc, Raytheon Technologies Corp, ...

Kansas City, MO, based Investment company Frontier Wealth Management LLC (Current Portfolio) buys Rio Tinto PLC, T-Mobile US Inc, Raytheon Technologies Corp, Recro Pharma Inc, New Relic Inc, sells Goldman Sachs Just Us Large Cap Equity ETF, Invesco BulletShares 2021 Corporate Bond ETF, United Parcel Service Inc, MGP Ingredients Inc, Silvergate Capital Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Frontier Wealth Management LLC.

Yahoo | February 4, 2022

Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention

SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new formulation development and cGMP manufacturing contract from a key department of the United States government. The contract focuses on supporting clinical devel

Yahoo | January 26, 2022

Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego

Latest Appointment Continues Build-Out of Leadership Team for San Diego OperationsSAN DIEGO and GAINESVILLE, Ga., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Eduardo Uribe as the company’s head of quality for Recro San Diego. Mr. Uribe has more than

Yahoo | January 19, 2022

Recro Reports Inducement Grants For New Staff

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles in technical operations. Inducement Equity Award In connection with the hiring of these personnel, the compensation committee of Recro’s board of directors approved

Yahoo | January 6, 2022

Recro to Present at H.C. Wainwright BioConnect 2022 Conference

SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10

Yahoo | January 3, 2022

Recro Pharma, Inc. (NASDAQ:REPH) Major Shareholder Sells $32,600.00 in Stock

Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Awm Investment Company, Inc. sold 20,000 shares of the companys stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $1.63, for a total value of $32,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed []

Dakota Financial News | December 18, 2021

Zacks Investment Research Lowers Recro Pharma (NASDAQ:REPH) to Hold

Zacks Investment Research cut shares of Recro Pharma (NASDAQ:REPH) from a buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The []

Dakota Financial News | December 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6025 seconds.